Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 Operating Income

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 (HROWM) currently reports a operating income of $-2.7M as of June 2026. That compares with $14M in the prior-year period — down 119.1% year over year. Use the charts on this page to explore Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's operating income history and peer comparisons.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's operating income decreased from $14M to $-2.7M — a 119.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 reported $-2.7M in operating income as of June 2026. That compares with $14M in the prior-year period — down 119.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-2.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Harrow- 11.875% NT REDEEM 31/12/2027 USD 25, and consider following HROWM for alerts when major investors trade the stock.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is classified in the Healthcare sector. On operating income, it currently shows $-2.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HROWM with unrelated industries.